A Phase 3 interventional study of RSVPreF3 OA investigational vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 52 sites in 6 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 6th largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 11th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 7 started in 2024.
This study's enrollment of 1,459 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 976 across the 17 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline: 1 open now, 5 under way, 3 of them phase 3. Of 33 finished, 30 (91%) have results posted.
Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 10th largest by enrollment, is one of 6 that started in 2024, is one of 21 in phase 3, and was the 33rd registered.
GlaxoSmithKline’s Respiratory Syncytial Virus Infections studies by the year they started, since 2013.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, from their registry updates:
Among GlaxoSmithKline’s 40 in Respiratory Syncytial Virus Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Written informed assent obtained from the participant (participant must be able to understand the informed assent) if he/she is less than the legal age prior to performance of any study-specific procedure.
Specific inclusion criteria for all participants in Cohort 1 and Cohort 3 (RSV-A-AIR Group) • A male or female participant 18-49 YOA at the time of the study intervention administration.
Participants should be diagnosed with at least 1 of the following medical conditions if considered medically stable by the investigator:
Chronic cardiopulmonary disease resulting in activity restricting symptoms or use of long term medication:
o (COPD)
o Asthma
o Cystic fibrosis
o Other chronic respiratory diseases: lung fibrosis, restrictive lung disease, interstitial lung disease, emphysema or bronchiectasis
o Chronic heart failure:
o Pre-existing Coronary Artery Disease (CAD) (CAD not otherwise specified)
Other diseases at increased risk for RSV disease:
Female participants of childbearing potential may be enrolled in the study, if the participant:
Specific inclusion criteria for all participants in Cohort 2 (RSV-OA Group):
Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease are allowed to participate in this study if considered medically stable by the investigator.
Exclusion Criteria:
Medical conditions
Prior/Concomitant therapy
Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or administration of long-acting immune-modifying treatments or planned administration at any time up to the End-of-study (EOS).
Up to 3 months prior to the study intervention administration:
Prior/Concurrent clinical study experience
Other exclusions:
Other exclusions for all participants:
Other exclusions for Cohort 1 and Cohort 3:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult (A) participants, 18-49 YOA, at increased risk (AIR) for RSV disease, received a single dose of RSVPreF3 OA investigational vaccine at Day 1. Participants in this group were considered for all study analyses, as per protocol.
Biological: RSVPreF3 OA investigational vaccine
Older adults (OA) participants, ≥60 YOA, received a single dose of RSVPreF3 OA investigational vaccine at Day 1.
Biological: RSVPreF3 OA investigational vaccine
Adult participants, 18-49 YOA, AIR for RSV disease, received a single dose of RSVPreF3 OA investigational vaccine at Day 1. Participants in this group were considered only for Participant flow, Baseline Characteristics and all safety analyses, as per protocol.
Biological: RSVPreF3 OA investigational vaccine
1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1.
Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)
RSV-A neutralizing titers are given as group GMTs and are expressed as Estimated dilution 60 (ED60)
Time frame: At Day 31
Part A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing Titers
SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) ≥4. RSV-A neutralizing titers are expressed as ED60.
Time frame: Day 31 compared with baseline (Day 1)
Part A: RSV-B Neutralizing Titers Expressed as Group GMTs
RSV-B neutralizing titers are given as group GMTs and are expressed as ED60.
Time frame: At Day 31
Part A: Percentage of Participants With SRR in RSV-B Neutralizing Titers
SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1-month post-study intervention administration over pre-study intervention administration) ≥ 4. RSV-B neutralizing titers are expressed as ED60.
Time frame: Day 31 compared with baseline (Day 1)
Part A and B: Number of Participants Reporting Any Solicited Administration Site Events
Assessed solicited administration site events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.
Time frame: Day 1 (post dose) to Day 4
Part A and B: Number of Participants Reporting Any Solicited Systemic Events
Assessed solicited systemic events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as temperature ≥38.0 degrees Celsius (°C), regardless of the location of measurement. The route for measuring temperature could be oral or axillary. Any = occurrence of the symptom regardless of intensity grade.
Time frame: Day 1 (post dose) to Day 4
Part A and B: Number of Participants Reporting Unsolicited Adverse Events (AEs)
An unsolicited AE wass an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs.
Time frame: Day 1 (post dose) to Day 30
Part A and B: Number of Participants Reporting Any Serious Adverse Events (SAEs), Related SAEs and Fatal SAEs
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.
Time frame: Throughout the study period (Day 1 to Month 6)
Part A and B: Number of Participants Reporting Any Adverse Events of Special Interest (AESIs)
AESIs assessed were potential immune-mediated diseases (pIMDs) and atrial fibrillation (AF). pIMDs were a subset of AESIs that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. AEs of AF were considered as AESI.
Time frame: Throughout the study period (Day 1 to Month 6)
Part A: RSV-A Neutralizing Titers Expressed as GMTs
RSV-A neutralizing titers are given as GMTs and are expressed as ED60.
Time frame: At Day 1 (pre-dose), at Month 1 and Month 6
Part A: RSV-B Neutralizing Titers Expressed as GMTs
RSV-B neutralizing titers are given as GMTs and are expressed as ED60.
Time frame: At Day 1 (pre-dose), at Month 1 and Month 6
| Milestone | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| Started | 426 | 429 | 603 |
| Completed | 414 | 422 | 586 |
| Not completed | 12 | 7 | 17 |
| Withdrew: Lost to follow-up | 9 | 5 | 13 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 2 | 1 |
| Withdrew: Other | 1 | 0 | 1 |
RSV-A neutralizing titers are given as group GMTs and are expressed as Estimated dilution 60 (ED60)
| Titer | Part A: RSV-A-AIR Group | Part A: RSV-OA Group |
|---|---|---|
| Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs) | 11910.1 (10927.3 to 12981.4) | 8593.6 (7904.3 to 9343.0) |
SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) ≥4. RSV-A neutralizing titers are expressed as ED60.
| Percentage of participants | Part A: RSV-A-AIR Group | Part A: RSV-OA Group |
|---|---|---|
| Part A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing Titers | 87.0 (83.3 to 90.2) | 77.7 (73.4 to 81.6) |
RSV-B neutralizing titers are given as group GMTs and are expressed as ED60.
| Titer | Part A: RSV-A-AIR Group | Part A: RSV-OA Group |
|---|---|---|
| Part A: RSV-B Neutralizing Titers Expressed as Group GMTs | 12496.4 (11482.4 to 13599.9) | 9089.7 (8373.7 to 9866.9) |
SRR is defined as the percentage of participants having a fold increase in neutralizing titers (1-month post-study intervention administration over pre-study intervention administration) ≥ 4. RSV-B neutralizing titers are expressed as ED60.
| Percentage of participants | Part A: RSV-A-AIR Group | Part A: RSV-OA Group |
|---|---|---|
| Part A: Percentage of Participants With SRR in RSV-B Neutralizing Titers | 87.2 (83.5 to 90.4) | 77.2 (72.9 to 81.2) |
Assessed solicited administration site events were pain, redness (erythema) and swelling at administration site. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| Pain | 358 | 246 | 422 |
| Redness | 36 | 23 | 52 |
| Swelling | 25 | 19 | 47 |
Assessed solicited systemic events were fever (pyrexia), headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever was defined as temperature ≥38.0 degrees Celsius (°C), regardless of the location of measurement. The route for measuring temperature could be oral or axillary. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| Fever | 25 | 11 | 26 |
| Headache | 198 | 78 | 250 |
| Myalgia | 284 | 169 | 331 |
| Arthralgia | 124 | 78 | 167 |
| Fatigue | 275 | 148 | 337 |
An unsolicited AE wass an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs included both serious and non-serious AEs.
| Participants | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| Part A and B: Number of Participants Reporting Unsolicited Adverse Events (AEs) | 72 | 76 | 118 |
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of the intensity grade or relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination.
| Participants | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| Any SAEs | 4 | 13 | 10 |
| Related SAEs | 0 | 0 | 0 |
| Fatal SAEs | 0 | 0 | 0 |
AESIs assessed were potential immune-mediated diseases (pIMDs) and atrial fibrillation (AF). pIMDs were a subset of AESIs that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. AEs of AF were considered as AESI.
| Participants | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| Part A and B: Number of Participants Reporting Any Adverse Events of Special Interest (AESIs) | 1 | 2 | 2 |
RSV-A neutralizing titers are given as GMTs and are expressed as ED60.
| Titer | Part A: RSV-A-AIR Group | Part A: RSV-OA Group |
|---|---|---|
| Day 1 | 892.6 (821.5 to 969.9) | 913.8 (837.2 to 997.4) |
| Month 1 | 11853.4 (10875.3 to 12919.5) | 8632.4 (7858.3 to 9482.6) |
| Month 6 | 4439.8 (4042.1 to 4876.7) | 3917.7 (3553.0 to 4319.7) |
RSV-B neutralizing titers are given as GMTs and are expressed as ED60.
| Titer | Part A: RSV-A-AIR Group | Part A: RSV-OA Group |
|---|---|---|
| Day 1 | 988.1 (905.9 to 1077.8) | 1045.1 (953.7 to 1145.2) |
| Month 1 | 12337.6 (11334.3 to 13429.7) | 9178.5 (8367.7 to 10067.8) |
| Month 6 | 4335.6 (3941.7 to 4769.0) | 4355.0 (3971.4 to 4775.7) |
Collected over Solicited AEs were collected from Day 1 (day of vaccination) up to Day 4 post-dose. Unsolicited AEs were collected from Day 1 up to Day 30 post-dose. All-cause mortality, SAEs, related SAEs, fatal SAEs and AESIs (including pIMDs and AF) were collected from Day 1 up to study end (Month 6). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: RSV-A-AIR Group | 0/426 (0%) | 4/426 (0.9%) | 386/426 (90.6%) |
| Part A: RSV-OA Group | 0/429 (0%) | 13/429 (3%) | 310/429 (72.3%) |
| Part B: RSV-A-AIR Group | 0/603 (0%) | 10/603 (1.7%) | 483/603 (80.1%) |
| Event | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| GastroenteritisInfections and infestations | 1/426 | 0/429 | 0/603 |
| Pulmonary sepsisInfections and infestations | 1/426 | 0/429 | 0/603 |
| Acute myocardial infarctionCardiac disorders | 1/426 | 0/429 | 0/603 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/426 | 0/429 | 0/603 |
| CellulitisInfections and infestations | 0/426 | 1/429 | 1/603 |
| PneumoniaInfections and infestations | 0/426 | 1/429 | 0/603 |
| SepsisInfections and infestations | 0/426 | 1/429 | 0/603 |
| Neurological symptomNervous system disorders | 0/426 | 1/429 | 0/603 |
| Transient global amnesiaNervous system disorders | 0/426 | 1/429 | 0/603 |
| Transient ischaemic attackNervous system disorders | 0/426 | 1/429 | 0/603 |
| Event | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group |
|---|---|---|---|
| Injection site painGeneral disorders | 358/426 | 246/429 | 422/603 |
| MyalgiaMusculoskeletal and connective tissue disorders | 284/426 | 169/429 | 331/603 |
| FatigueGeneral disorders | 275/426 | 148/429 | 338/603 |
| HeadacheNervous system disorders | 198/426 | 78/429 | 250/603 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 126/426 | 81/429 | 167/603 |
| Injection site erythemaGeneral disorders | 37/426 | 23/429 | 52/603 |
| Injection site swellingGeneral disorders | 25/426 | 19/429 | 47/603 |
| PyrexiaGeneral disorders | 26/426 | 12/429 | 29/603 |
| NauseaGastrointestinal disorders | 14/426 | 2/429 | 12/603 |
| ChillsGeneral disorders | 5/426 | 2/429 | 13/603 |
| Age, Continuous(YEARS) | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group | Total |
|---|---|---|---|---|
| Mean | 38.9 ± 7.8 | 68.6 ± 5.7 | 38.1 ± 8.7 | 47.3 ± 15.7 |
| Sex: Female, Male(Participants) | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group | Total |
|---|---|---|---|---|
| Female | 247 | 220 | 347 | 814 |
| Male | 179 | 209 | 256 | 644 |
| Race/Ethnicity, Customized(Participants) | Part A: RSV-A-AIR Group | Part A: RSV-OA Group | Part B: RSV-A-AIR Group | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 8 | 0 | 11 | 19 |
| Asian | 60 | 50 | 64 | 174 |
| Balck or African American | 77 | 54 | 181 | 312 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 11 | 11 |
| White | 255 | 302 | 274 | 831 |
| Not reported | 3 | 1 | 0 | 4 |
| Unknown | 4 | 0 | 3 | 7 |
| Multiple Race Categories | 19 | 22 | 59 | 100 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Apr 2024 to primary completion in Jul 2024, 3 months.
Results were first posted in Sep 2025, 1 year 1 month after primary completion.
Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 3 months is below that.
Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arexvy
Respiratory Syncytial Virus Infections →